Impact of Cooling Mats on Vasomotor Symptoms in Patients Receiving Endocrine Therapy

Inclusion Criteria: Age ≥ 18 years at time of consent Histologically confirmed diagnosis of breast cancer or prostate cancer Currently receiving endocrine therapy (e.g., tamoxifen, aromatase inhibitors, ovarian suppression therapy, androgen deprivation therapy) Self-reported vasomotor symptoms (e.g., hot flushes and/or night sweats) occurring at least once daily during the 2 weeks prior to screening Ability to understand the study procedures and provide written informed consent Exclusion Criteria: Prior use of cooling mat devices specifically for management of vasomotor symptoms within the past 3 months Known hypersensitivity or allergy to polyvinyl chloride (PVC) or any component of the cooling mat device Cognitive impairment, psychiatric condition, or other medical condition that, in the opinion of the investigator, would interfere with adherence to study procedures Concurrent participation in another interventional clinical trial for management of vasomotor symptoms